FourSmile Named to 2023 Future Healthcare Top 100 List as "China Innovative Healthcare Service Enterprise" | Oasis Vitality

Recently, the 7th Future Healthcare 100 Conference, themed "East and West," kicked off in Shanghai, unveiling the 2023 Future Healthcare 100 list. Launched in 2015, the Future Healthcare 100 is China's first innovation-focused healthcare ranking for unlisted companies, created by VB100, VBData, and Eggshell Research Institute. Its mission is to identify Chinese innovators who truly represent the future of healthcare, uncover the core forces driving China's healthcare industry, and accelerate innovation and transformation in the health sector. Over seven years, the Future Healthcare 100 evaluation system has steadily expanded, gradually building a global innovation ecosystem that covers enterprises, investment institutions, and industrial parks, while extending into product and technology innovation categories. Among this year's honorees, Oasis Capital portfolio company FourSmile was named "China Innovative Healthcare Service Enterprise."

As the world shifts and noise overwhelms, Oasis Capital will continue to apply a "top-down" research methodology, drawing on the experience of ecosystem entrepreneurs to deliver sustained signals for the long term. We remain anchored by "demographic structure" and "technological innovation" as our entry points, focusing on robotics, artificial intelligence, and technology services, and making long-term investments in the most vital entrepreneurs. Celebrating Vitality.

Click "Read More" to view the full list.

Oasis Capital is a new-generation Chinese venture capital firm dedicated to discovering the most vital entrepreneurs of the next decade and growing alongside them to create long-term value. "Celebrating Vitality" is Oasis's vision and mission. This vitality — the force we champion — is both the direction of structural transformation in our era and the resilience and evolutionary power of entrepreneurs themselves.

Oasis Capital focuses on early and growth-stage investments, writing checks from $3 million to $30 million, with emphasis on robotics, artificial intelligence, and technology services. We support the upgrade of China's technology-driven new services.